nodes	percent_of_prediction	percent_of_DWPC	metapath
Sucralfate—Venous thrombosis—Carboplatin—urinary bladder cancer	0.0271	0.116	CcSEcCtD
Sucralfate—PGA5—renal system—urinary bladder cancer	0.0255	0.105	CbGeAlD
Sucralfate—Fluid overload—Carboplatin—urinary bladder cancer	0.0235	0.101	CcSEcCtD
Sucralfate—PGA5—female reproductive system—urinary bladder cancer	0.0204	0.0841	CbGeAlD
Sucralfate—FGB—renal system—urinary bladder cancer	0.0173	0.0714	CbGeAlD
Sucralfate—Extravasation—Carboplatin—urinary bladder cancer	0.0167	0.0717	CcSEcCtD
Sucralfate—EGF—prostate gland—urinary bladder cancer	0.0159	0.0655	CbGeAlD
Sucralfate—FGA—Podofilox—Etoposide—urinary bladder cancer	0.0149	1	CbGdCrCtD
Sucralfate—FGA—renal system—urinary bladder cancer	0.0148	0.0611	CbGeAlD
Sucralfate—FGF2—prostate gland—urinary bladder cancer	0.014	0.0578	CbGeAlD
Sucralfate—FGB—female reproductive system—urinary bladder cancer	0.0139	0.0572	CbGeAlD
Sucralfate—Haemolysis—Cisplatin—urinary bladder cancer	0.0135	0.0577	CcSEcCtD
Sucralfate—Extravasation—Mitomycin—urinary bladder cancer	0.0124	0.0533	CcSEcCtD
Sucralfate—Phlebitis—Carboplatin—urinary bladder cancer	0.0123	0.0527	CcSEcCtD
Sucralfate—FGA—female reproductive system—urinary bladder cancer	0.0119	0.0489	CbGeAlD
Sucralfate—EGF—epithelium—urinary bladder cancer	0.0117	0.0481	CbGeAlD
Sucralfate—EGF—smooth muscle tissue—urinary bladder cancer	0.0113	0.0464	CbGeAlD
Sucralfate—EGF—renal system—urinary bladder cancer	0.0108	0.0446	CbGeAlD
Sucralfate—EGF—urethra—urinary bladder cancer	0.0106	0.0438	CbGeAlD
Sucralfate—FGG—lymph node—urinary bladder cancer	0.0105	0.0433	CbGeAlD
Sucralfate—FGF2—smooth muscle tissue—urinary bladder cancer	0.00993	0.0409	CbGeAlD
Sucralfate—FGF2—urethra—urinary bladder cancer	0.00939	0.0387	CbGeAlD
Sucralfate—EGF—female reproductive system—urinary bladder cancer	0.00868	0.0357	CbGeAlD
Sucralfate—Venous thrombosis—Cisplatin—urinary bladder cancer	0.00793	0.034	CcSEcCtD
Sucralfate—EGF—vagina—urinary bladder cancer	0.00785	0.0323	CbGeAlD
Sucralfate—FGF2—vagina—urinary bladder cancer	0.00692	0.0285	CbGeAlD
Sucralfate—Fluid overload—Cisplatin—urinary bladder cancer	0.00689	0.0295	CcSEcCtD
Sucralfate—Extravasation—Thiotepa—urinary bladder cancer	0.00626	0.0268	CcSEcCtD
Sucralfate—Extravasation—Gemcitabine—urinary bladder cancer	0.00527	0.0226	CcSEcCtD
Sucralfate—Extravasation—Fluorouracil—urinary bladder cancer	0.00518	0.0222	CcSEcCtD
Sucralfate—Infection—Carboplatin—urinary bladder cancer	0.00518	0.0222	CcSEcCtD
Sucralfate—EGF—lymph node—urinary bladder cancer	0.00508	0.0209	CbGeAlD
Sucralfate—Extravasation—Cisplatin—urinary bladder cancer	0.00491	0.021	CcSEcCtD
Sucralfate—Extravasation—Etoposide—urinary bladder cancer	0.0045	0.0193	CcSEcCtD
Sucralfate—FGF2—lymph node—urinary bladder cancer	0.00448	0.0184	CbGeAlD
Sucralfate—Body temperature increased—Valrubicin—urinary bladder cancer	0.00445	0.019	CcSEcCtD
Sucralfate—Body temperature increased—Carboplatin—urinary bladder cancer	0.00412	0.0176	CcSEcCtD
Sucralfate—Venous thrombosis—Epirubicin—urinary bladder cancer	0.00407	0.0175	CcSEcCtD
Sucralfate—Oedema—Mitomycin—urinary bladder cancer	0.00388	0.0166	CcSEcCtD
Sucralfate—Venous thrombosis—Doxorubicin—urinary bladder cancer	0.00377	0.0161	CcSEcCtD
Sucralfate—Phlebitis—Cisplatin—urinary bladder cancer	0.00361	0.0155	CcSEcCtD
Sucralfate—Lung disorder—Methotrexate—urinary bladder cancer	0.00332	0.0142	CcSEcCtD
Sucralfate—Phlebitis—Etoposide—urinary bladder cancer	0.00331	0.0142	CcSEcCtD
Sucralfate—Hyponatraemia—Cisplatin—urinary bladder cancer	0.00312	0.0134	CcSEcCtD
Sucralfate—Lung disorder—Epirubicin—urinary bladder cancer	0.00311	0.0133	CcSEcCtD
Sucralfate—Body temperature increased—Mitomycin—urinary bladder cancer	0.00306	0.0131	CcSEcCtD
Sucralfate—Lung disorder—Doxorubicin—urinary bladder cancer	0.00288	0.0123	CcSEcCtD
Sucralfate—Extravasation—Methotrexate—urinary bladder cancer	0.00269	0.0115	CcSEcCtD
Sucralfate—Extravasation—Epirubicin—urinary bladder cancer	0.00252	0.0108	CcSEcCtD
Sucralfate—Extravasation—Doxorubicin—urinary bladder cancer	0.00233	0.00999	CcSEcCtD
Sucralfate—Infection—Thiotepa—urinary bladder cancer	0.00194	0.00829	CcSEcCtD
Sucralfate—Phlebitis—Epirubicin—urinary bladder cancer	0.00185	0.00794	CcSEcCtD
Sucralfate—ALB—lymph node—urinary bladder cancer	0.00175	0.00723	CbGeAlD
Sucralfate—Phlebitis—Doxorubicin—urinary bladder cancer	0.00171	0.00735	CcSEcCtD
Sucralfate—Oedema—Gemcitabine—urinary bladder cancer	0.00164	0.00702	CcSEcCtD
Sucralfate—Infection—Gemcitabine—urinary bladder cancer	0.00163	0.00698	CcSEcCtD
Sucralfate—Oedema—Fluorouracil—urinary bladder cancer	0.00161	0.0069	CcSEcCtD
Sucralfate—Hyponatraemia—Epirubicin—urinary bladder cancer	0.0016	0.00687	CcSEcCtD
Sucralfate—Infection—Fluorouracil—urinary bladder cancer	0.0016	0.00686	CcSEcCtD
Sucralfate—Body temperature increased—Thiotepa—urinary bladder cancer	0.00154	0.0066	CcSEcCtD
Sucralfate—Oedema—Cisplatin—urinary bladder cancer	0.00153	0.00655	CcSEcCtD
Sucralfate—Infection—Cisplatin—urinary bladder cancer	0.00152	0.0065	CcSEcCtD
Sucralfate—Hyponatraemia—Doxorubicin—urinary bladder cancer	0.00148	0.00635	CcSEcCtD
Sucralfate—Infection—Etoposide—urinary bladder cancer	0.00139	0.00596	CcSEcCtD
Sucralfate—Body temperature increased—Gemcitabine—urinary bladder cancer	0.0013	0.00555	CcSEcCtD
Sucralfate—Body temperature increased—Fluorouracil—urinary bladder cancer	0.00127	0.00546	CcSEcCtD
Sucralfate—Body temperature increased—Cisplatin—urinary bladder cancer	0.00121	0.00517	CcSEcCtD
Sucralfate—Body temperature increased—Etoposide—urinary bladder cancer	0.00111	0.00474	CcSEcCtD
Sucralfate—Infection—Methotrexate—urinary bladder cancer	0.000833	0.00357	CcSEcCtD
Sucralfate—Oedema—Epirubicin—urinary bladder cancer	0.000785	0.00336	CcSEcCtD
Sucralfate—Infection—Epirubicin—urinary bladder cancer	0.00078	0.00334	CcSEcCtD
Sucralfate—Oedema—Doxorubicin—urinary bladder cancer	0.000726	0.00311	CcSEcCtD
Sucralfate—Infection—Doxorubicin—urinary bladder cancer	0.000721	0.00309	CcSEcCtD
Sucralfate—Body temperature increased—Methotrexate—urinary bladder cancer	0.000663	0.00284	CcSEcCtD
Sucralfate—Body temperature increased—Epirubicin—urinary bladder cancer	0.00062	0.00266	CcSEcCtD
Sucralfate—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000574	0.00246	CcSEcCtD
Sucralfate—EGF—Adaptive Immune System—SRC—urinary bladder cancer	0.000102	0.000201	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—CREBBP—urinary bladder cancer	0.000102	0.0002	CbGpPWpGaD
Sucralfate—EGF—Disease—FGFR3—urinary bladder cancer	0.000102	0.0002	CbGpPWpGaD
Sucralfate—FGF2—Immune System—IFNA2—urinary bladder cancer	0.000101	0.000199	CbGpPWpGaD
Sucralfate—FGA—Disease—CDKN1A—urinary bladder cancer	9.94e-05	0.000195	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—CREBBP—urinary bladder cancer	9.92e-05	0.000195	CbGpPWpGaD
Sucralfate—FGA—Disease—PTEN—urinary bladder cancer	9.91e-05	0.000195	CbGpPWpGaD
Sucralfate—EGF—Hemostasis—KRAS—urinary bladder cancer	9.81e-05	0.000193	CbGpPWpGaD
Sucralfate—FGF2—Signaling by NGF—KRAS—urinary bladder cancer	9.8e-05	0.000193	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—S100B—urinary bladder cancer	9.8e-05	0.000193	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—IGF1—urinary bladder cancer	9.8e-05	0.000193	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—CREBBP—urinary bladder cancer	9.72e-05	0.000191	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—CREBBP—urinary bladder cancer	9.72e-05	0.000191	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—CDH1—urinary bladder cancer	9.72e-05	0.000191	CbGpPWpGaD
Sucralfate—FGF2—Developmental Biology—ERBB2—urinary bladder cancer	9.67e-05	0.00019	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—IGF1—urinary bladder cancer	9.6e-05	0.000189	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—IGF1—urinary bladder cancer	9.6e-05	0.000189	CbGpPWpGaD
Sucralfate—FGF2—Immune System—S100B—urinary bladder cancer	9.59e-05	0.000189	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GSTZ1—urinary bladder cancer	9.48e-05	0.000186	CbGpPWpGaD
Sucralfate—FGA—Disease—EP300—urinary bladder cancer	9.45e-05	0.000186	CbGpPWpGaD
Sucralfate—EGF—Immune System—CREBBP—urinary bladder cancer	9.38e-05	0.000184	CbGpPWpGaD
Sucralfate—EGF—Innate Immune System—EGFR—urinary bladder cancer	9.35e-05	0.000184	CbGpPWpGaD
Sucralfate—EGF—Immune System—CDH1—urinary bladder cancer	9.31e-05	0.000183	CbGpPWpGaD
Sucralfate—ALB—Selenium Micronutrient Network—TNF—urinary bladder cancer	9.25e-05	0.000182	CbGpPWpGaD
Sucralfate—FGA—Disease—SRC—urinary bladder cancer	9.19e-05	0.000181	CbGpPWpGaD
Sucralfate—ALB—Metabolism—NAT1—urinary bladder cancer	8.99e-05	0.000177	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GSTO2—urinary bladder cancer	8.99e-05	0.000177	CbGpPWpGaD
Sucralfate—EGF—Adaptive Immune System—EGFR—urinary bladder cancer	8.98e-05	0.000176	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—RHOA—urinary bladder cancer	8.98e-05	0.000176	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	8.84e-05	0.000174	CbGpPWpGaD
Sucralfate—EGF—Innate Immune System—KRAS—urinary bladder cancer	8.83e-05	0.000174	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—NCOR1—urinary bladder cancer	8.81e-05	0.000173	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—RHOA—urinary bladder cancer	8.79e-05	0.000173	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—RHOA—urinary bladder cancer	8.79e-05	0.000173	CbGpPWpGaD
Sucralfate—EGF—Hemostasis—TP53—urinary bladder cancer	8.72e-05	0.000171	CbGpPWpGaD
Sucralfate—EGF—Disease—CREBBP—urinary bladder cancer	8.66e-05	0.00017	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—RBX1—urinary bladder cancer	8.56e-05	0.000168	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—ERBB2—urinary bladder cancer	8.54e-05	0.000168	CbGpPWpGaD
Sucralfate—EGF—Adaptive Immune System—KRAS—urinary bladder cancer	8.48e-05	0.000167	CbGpPWpGaD
Sucralfate—EGF—Hemostasis—HRAS—urinary bladder cancer	8.34e-05	0.000164	CbGpPWpGaD
Sucralfate—FGF2—Signaling by NGF—HRAS—urinary bladder cancer	8.33e-05	0.000164	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—ERBB2—urinary bladder cancer	8.31e-05	0.000163	CbGpPWpGaD
Sucralfate—FGF2—Developmental Biology—MMP9—urinary bladder cancer	8.29e-05	0.000163	CbGpPWpGaD
Sucralfate—FGA—Disease—MYC—urinary bladder cancer	8.24e-05	0.000162	CbGpPWpGaD
Sucralfate—ALB—Metabolism—UGT2B7—urinary bladder cancer	8.22e-05	0.000162	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—ERBB2—urinary bladder cancer	8.2e-05	0.000161	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—ERBB2—urinary bladder cancer	8.14e-05	0.00016	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—ERBB2—urinary bladder cancer	8.14e-05	0.00016	CbGpPWpGaD
Sucralfate—FGA—Disease—EGFR—urinary bladder cancer	8.06e-05	0.000158	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—TSC1—urinary bladder cancer	8.05e-05	0.000158	CbGpPWpGaD
Sucralfate—FGF2—Disease—NCOR1—urinary bladder cancer	7.96e-05	0.000157	CbGpPWpGaD
Sucralfate—ALB—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	7.91e-05	0.000155	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—CXCL8—urinary bladder cancer	7.88e-05	0.000155	CbGpPWpGaD
Sucralfate—FGF2—Developmental Biology—EP300—urinary bladder cancer	7.86e-05	0.000155	CbGpPWpGaD
Sucralfate—EGF—Immune System—ERBB2—urinary bladder cancer	7.86e-05	0.000154	CbGpPWpGaD
Sucralfate—EGF—Disease—RHOA—urinary bladder cancer	7.84e-05	0.000154	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—TERT—urinary bladder cancer	7.77e-05	0.000153	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—CXCL8—urinary bladder cancer	7.72e-05	0.000152	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—CXCL8—urinary bladder cancer	7.72e-05	0.000152	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—JAG1—urinary bladder cancer	7.66e-05	0.000151	CbGpPWpGaD
Sucralfate—FGF2—Developmental Biology—SRC—urinary bladder cancer	7.65e-05	0.00015	CbGpPWpGaD
Sucralfate—ALB—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	7.64e-05	0.00015	CbGpPWpGaD
Sucralfate—FGA—Disease—KRAS—urinary bladder cancer	7.61e-05	0.00015	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—IL2—urinary bladder cancer	7.53e-05	0.000148	CbGpPWpGaD
Sucralfate—EGF—Innate Immune System—HRAS—urinary bladder cancer	7.51e-05	0.000148	CbGpPWpGaD
Sucralfate—FGF2—Disease—ERCC2—urinary bladder cancer	7.49e-05	0.000147	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CYP4B1—urinary bladder cancer	7.4e-05	0.000145	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—IL2—urinary bladder cancer	7.38e-05	0.000145	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—IL2—urinary bladder cancer	7.38e-05	0.000145	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—CCND1—urinary bladder cancer	7.34e-05	0.000144	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—CDKN1A—urinary bladder cancer	7.3e-05	0.000143	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—PTEN—urinary bladder cancer	7.28e-05	0.000143	CbGpPWpGaD
Sucralfate—EGF—Disease—ERBB2—urinary bladder cancer	7.26e-05	0.000143	CbGpPWpGaD
Sucralfate—ALB—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	7.25e-05	0.000142	CbGpPWpGaD
Sucralfate—EGF—Adaptive Immune System—HRAS—urinary bladder cancer	7.21e-05	0.000142	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—CCND1—urinary bladder cancer	7.19e-05	0.000141	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—CCND1—urinary bladder cancer	7.19e-05	0.000141	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—MMP9—urinary bladder cancer	7.13e-05	0.00014	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—FGFR3—urinary bladder cancer	7.13e-05	0.00014	CbGpPWpGaD
Sucralfate—EGF—Immune System—IL2—urinary bladder cancer	7.12e-05	0.00014	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—CDKN1A—urinary bladder cancer	7.1e-05	0.00014	CbGpPWpGaD
Sucralfate—EGF—Disease—PTGS2—urinary bladder cancer	7.09e-05	0.000139	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—PTEN—urinary bladder cancer	7.09e-05	0.000139	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—IFNA2—urinary bladder cancer	7.05e-05	0.000139	CbGpPWpGaD
Sucralfate—FGF2—Disease—MTHFR—urinary bladder cancer	7.04e-05	0.000138	CbGpPWpGaD
Sucralfate—FGF2—Disease—TERT—urinary bladder cancer	7.02e-05	0.000138	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—CDKN1A—urinary bladder cancer	7.01e-05	0.000138	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—PTEN—urinary bladder cancer	6.99e-05	0.000137	CbGpPWpGaD
Sucralfate—ALB—Metabolism—SLC19A1—urinary bladder cancer	6.99e-05	0.000137	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—MMP9—urinary bladder cancer	6.98e-05	0.000137	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—MMP9—urinary bladder cancer	6.98e-05	0.000137	CbGpPWpGaD
Sucralfate—FGF2—Immune System—FGFR3—urinary bladder cancer	6.98e-05	0.000137	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—CDKN1A—urinary bladder cancer	6.96e-05	0.000137	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—CDKN1A—urinary bladder cancer	6.96e-05	0.000137	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—EP300—urinary bladder cancer	6.94e-05	0.000136	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—PTEN—urinary bladder cancer	6.94e-05	0.000136	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—PTEN—urinary bladder cancer	6.94e-05	0.000136	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—ESR1—urinary bladder cancer	6.92e-05	0.000136	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PRSS3—urinary bladder cancer	6.81e-05	0.000134	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—EP300—urinary bladder cancer	6.76e-05	0.000133	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—SRC—urinary bladder cancer	6.75e-05	0.000133	CbGpPWpGaD
Sucralfate—EGF—Immune System—CDKN1A—urinary bladder cancer	6.72e-05	0.000132	CbGpPWpGaD
Sucralfate—FGF2—Developmental Biology—EGFR—urinary bladder cancer	6.7e-05	0.000132	CbGpPWpGaD
Sucralfate—EGF—Immune System—PTEN—urinary bladder cancer	6.7e-05	0.000132	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—EP300—urinary bladder cancer	6.62e-05	0.00013	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—EP300—urinary bladder cancer	6.62e-05	0.00013	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—SRC—urinary bladder cancer	6.57e-05	0.000129	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—SRC—urinary bladder cancer	6.48e-05	0.000127	CbGpPWpGaD
Sucralfate—FGA—Disease—HRAS—urinary bladder cancer	6.47e-05	0.000127	CbGpPWpGaD
Sucralfate—FGF2—Disease—FGFR3—urinary bladder cancer	6.44e-05	0.000127	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—SRC—urinary bladder cancer	6.44e-05	0.000127	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—SRC—urinary bladder cancer	6.44e-05	0.000127	CbGpPWpGaD
Sucralfate—EGF—Immune System—EP300—urinary bladder cancer	6.39e-05	0.000126	CbGpPWpGaD
Sucralfate—FGF2—Developmental Biology—TNF—urinary bladder cancer	6.38e-05	0.000125	CbGpPWpGaD
Sucralfate—FGF2—Developmental Biology—KRAS—urinary bladder cancer	6.33e-05	0.000124	CbGpPWpGaD
Sucralfate—EGF—Immune System—SRC—urinary bladder cancer	6.21e-05	0.000122	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—S100B—urinary bladder cancer	6.2e-05	0.000122	CbGpPWpGaD
Sucralfate—EGF—Disease—CDKN1A—urinary bladder cancer	6.2e-05	0.000122	CbGpPWpGaD
Sucralfate—EGF—Disease—PTEN—urinary bladder cancer	6.19e-05	0.000122	CbGpPWpGaD
Sucralfate—ALB—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	6.08e-05	0.000119	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—CREBBP—urinary bladder cancer	6.07e-05	0.000119	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—IGF1—urinary bladder cancer	5.99e-05	0.000118	CbGpPWpGaD
Sucralfate—FGF2—Immune System—CREBBP—urinary bladder cancer	5.94e-05	0.000117	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—EGFR—urinary bladder cancer	5.92e-05	0.000116	CbGpPWpGaD
Sucralfate—EGF—Disease—EP300—urinary bladder cancer	5.9e-05	0.000116	CbGpPWpGaD
Sucralfate—FGF2—Immune System—CDH1—urinary bladder cancer	5.89e-05	0.000116	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—MYC—urinary bladder cancer	5.89e-05	0.000116	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—MYC—urinary bladder cancer	5.77e-05	0.000113	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—MYC—urinary bladder cancer	5.77e-05	0.000113	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—EGFR—urinary bladder cancer	5.76e-05	0.000113	CbGpPWpGaD
Sucralfate—EGF—Disease—SRC—urinary bladder cancer	5.74e-05	0.000113	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—EGFR—urinary bladder cancer	5.68e-05	0.000112	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—EGFR—urinary bladder cancer	5.64e-05	0.000111	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—EGFR—urinary bladder cancer	5.64e-05	0.000111	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—KRAS—urinary bladder cancer	5.59e-05	0.00011	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—NCOR1—urinary bladder cancer	5.58e-05	0.00011	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—RHOA—urinary bladder cancer	5.49e-05	0.000108	CbGpPWpGaD
Sucralfate—FGF2—Disease—CREBBP—urinary bladder cancer	5.48e-05	0.000108	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.46e-05	0.000107	CbGpPWpGaD
Sucralfate—EGF—Immune System—EGFR—urinary bladder cancer	5.45e-05	0.000107	CbGpPWpGaD
Sucralfate—ALB—Metabolism—TYMP—urinary bladder cancer	5.44e-05	0.000107	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—KRAS—urinary bladder cancer	5.44e-05	0.000107	CbGpPWpGaD
Sucralfate—FGF2—Developmental Biology—HRAS—urinary bladder cancer	5.38e-05	0.000106	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—KRAS—urinary bladder cancer	5.37e-05	0.000106	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—KRAS—urinary bladder cancer	5.33e-05	0.000105	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—KRAS—urinary bladder cancer	5.33e-05	0.000105	CbGpPWpGaD
Sucralfate—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	5.31e-05	0.000104	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.23e-05	0.000103	CbGpPWpGaD
Sucralfate—EGF—Immune System—KRAS—urinary bladder cancer	5.15e-05	0.000101	CbGpPWpGaD
Sucralfate—EGF—Disease—MYC—urinary bladder cancer	5.14e-05	0.000101	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—ERBB2—urinary bladder cancer	5.08e-05	9.98e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—EGFR—urinary bladder cancer	5.03e-05	9.88e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—PLAU—urinary bladder cancer	5.01e-05	9.84e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—ERBB2—urinary bladder cancer	4.97e-05	9.77e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—RHOA—urinary bladder cancer	4.96e-05	9.75e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—NAT2—urinary bladder cancer	4.92e-05	9.68e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—TERT—urinary bladder cancer	4.92e-05	9.66e-05	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—TP53—urinary bladder cancer	4.84e-05	9.5e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—CXCL8—urinary bladder cancer	4.82e-05	9.47e-05	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—HRAS—urinary bladder cancer	4.75e-05	9.34e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—KRAS—urinary bladder cancer	4.75e-05	9.34e-05	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—TP53—urinary bladder cancer	4.74e-05	9.31e-05	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—TP53—urinary bladder cancer	4.74e-05	9.31e-05	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—HRAS—urinary bladder cancer	4.63e-05	9.09e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—IL2—urinary bladder cancer	4.6e-05	9.05e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—ERBB2—urinary bladder cancer	4.59e-05	9.02e-05	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—HRAS—urinary bladder cancer	4.56e-05	8.97e-05	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—HRAS—urinary bladder cancer	4.53e-05	8.9e-05	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—HRAS—urinary bladder cancer	4.53e-05	8.9e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—FGFR3—urinary bladder cancer	4.51e-05	8.86e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—IL2—urinary bladder cancer	4.51e-05	8.86e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—PTGS2—urinary bladder cancer	4.49e-05	8.82e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—CCND1—urinary bladder cancer	4.49e-05	8.82e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—ESR1—urinary bladder cancer	4.38e-05	8.61e-05	CbGpPWpGaD
Sucralfate—EGF—Immune System—HRAS—urinary bladder cancer	4.37e-05	8.6e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—MMP9—urinary bladder cancer	4.36e-05	8.56e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—CDKN1A—urinary bladder cancer	4.34e-05	8.53e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—PTEN—urinary bladder cancer	4.33e-05	8.51e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—CDKN1A—urinary bladder cancer	4.25e-05	8.35e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—RRM2—urinary bladder cancer	4.25e-05	8.35e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—PTEN—urinary bladder cancer	4.24e-05	8.33e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—EP300—urinary bladder cancer	4.13e-05	8.12e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—CREBBP—urinary bladder cancer	4.13e-05	8.12e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—IGF1—urinary bladder cancer	4.08e-05	8.01e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—EP300—urinary bladder cancer	4.04e-05	7.95e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—HRAS—urinary bladder cancer	4.04e-05	7.94e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—SRC—urinary bladder cancer	4.02e-05	7.9e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ENO2—urinary bladder cancer	3.94e-05	7.74e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—HPGDS—urinary bladder cancer	3.94e-05	7.74e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—SRC—urinary bladder cancer	3.93e-05	7.73e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—CDKN1A—urinary bladder cancer	3.92e-05	7.71e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—PTEN—urinary bladder cancer	3.92e-05	7.7e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.91e-05	7.69e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CREBBP—urinary bladder cancer	3.84e-05	7.55e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GSTT1—urinary bladder cancer	3.82e-05	7.5e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—IGF1—urinary bladder cancer	3.79e-05	7.45e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.76e-05	7.39e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—RHOA—urinary bladder cancer	3.74e-05	7.34e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—EP300—urinary bladder cancer	3.73e-05	7.34e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—SRC—urinary bladder cancer	3.63e-05	7.14e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—MYC—urinary bladder cancer	3.6e-05	7.08e-05	CbGpPWpGaD
Sucralfate—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.57e-05	7.03e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—EGFR—urinary bladder cancer	3.52e-05	6.92e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—RHOA—urinary bladder cancer	3.47e-05	6.83e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—EGFR—urinary bladder cancer	3.45e-05	6.77e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—KRAS—urinary bladder cancer	3.33e-05	6.54e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—KRAS—urinary bladder cancer	3.26e-05	6.4e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—MYC—urinary bladder cancer	3.25e-05	6.39e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—ERBB2—urinary bladder cancer	3.22e-05	6.32e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—EGFR—urinary bladder cancer	3.18e-05	6.25e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—NQO1—urinary bladder cancer	3.17e-05	6.24e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—IL2—urinary bladder cancer	3.13e-05	6.16e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.08e-05	6.05e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CXCL8—urinary bladder cancer	3.05e-05	5.99e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—KRAS—urinary bladder cancer	3.01e-05	5.91e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—TP53—urinary bladder cancer	2.96e-05	5.81e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—IL2—urinary bladder cancer	2.91e-05	5.73e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CCND1—urinary bladder cancer	2.84e-05	5.58e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—HRAS—urinary bladder cancer	2.83e-05	5.56e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—EP300—urinary bladder cancer	2.81e-05	5.53e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—HRAS—urinary bladder cancer	2.77e-05	5.44e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MMP9—urinary bladder cancer	2.76e-05	5.42e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CDKN1A—urinary bladder cancer	2.75e-05	5.4e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PTEN—urinary bladder cancer	2.74e-05	5.39e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—SRC—urinary bladder cancer	2.73e-05	5.37e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.68e-05	5.28e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GSTP1—urinary bladder cancer	2.65e-05	5.2e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—EP300—urinary bladder cancer	2.62e-05	5.14e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.56e-05	5.03e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—HRAS—urinary bladder cancer	2.56e-05	5.02e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—SRC—urinary bladder cancer	2.54e-05	5e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—TYMS—urinary bladder cancer	2.46e-05	4.84e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—NCOR1—urinary bladder cancer	2.43e-05	4.78e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GSTM1—urinary bladder cancer	2.43e-05	4.78e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GPX1—urinary bladder cancer	2.33e-05	4.58e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ERCC2—urinary bladder cancer	2.29e-05	4.49e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MYC—urinary bladder cancer	2.28e-05	4.48e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—KRAS—urinary bladder cancer	2.26e-05	4.45e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—EGFR—urinary bladder cancer	2.23e-05	4.38e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—MTHFR—urinary bladder cancer	2.15e-05	4.22e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—KRAS—urinary bladder cancer	2.11e-05	4.14e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—TP53—urinary bladder cancer	2.01e-05	3.96e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—HRAS—urinary bladder cancer	1.92e-05	3.78e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—TP53—urinary bladder cancer	1.87e-05	3.68e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—HRAS—urinary bladder cancer	1.79e-05	3.52e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PPARG—urinary bladder cancer	1.74e-05	3.43e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CREBBP—urinary bladder cancer	1.67e-05	3.29e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PTGS2—urinary bladder cancer	1.37e-05	2.69e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PTEN—urinary bladder cancer	1.2e-05	2.35e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—EP300—urinary bladder cancer	1.14e-05	2.24e-05	CbGpPWpGaD
